anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method includes receiving image data of an examination object. A first temporary data record is created by applying a first correction to the image data. A further temporary data record is created by applying a further correction to the image data. The further correction at least partially corresponds to the first correction. A trained function is applied to input data that is based on the first temporary data record and the further temporary data record. A parameter of the trained function is based on an image quality metric. It is determined whether the first temporary data record has a higher image quality compared with the further temporary data record. When a result is positive, the first temporary data record is provided as the corrected medical image data. When the result is negative, the further temporary data record is provided as the image data, and part of the method is repeated.
BACKGROUND-AIM: Pregnancy induces physiological changes that can affect serologic and immunologic markers, potentially resulting in lower or undetectable haptoglobin values compared to non-pregnant counterparts. Such variations may lead to inaccurate diagnosis of hemolysis.
METHODS: We report a case of a patient in second trimester of pregnancy receiving induction chemotherapy due to B-cell acute lymphocytic leukemia with undetectable haptoglobin levels in a routine laboratory sample collected less than 12 h posttransfusion of red cell unit. Despite undetectable haptoglobin, lactate dehydrogenase (LD) was within reference intervals (RI). The patient was evaluated for acute hemolytic transfusion reaction (AHTR) and followed up. Haptoglobin levels showed an upward trend during follow-up visits, reaching 15 mg/dL, and within RI in the third trimester.
RESULTS: The patient did not meet the Center for Disease Control (CDC) criteria for AHTR. Alternative explanations for the observed laboratory findings were explored. Undetectable haptoglobin levels were attributed to various factors, including recent RBC transfusion, pregnancy-related physiological changes, and potential hyperhydration treatment plan due to chemotherapy.
CONCLUSION: This case underscores the importance of cautious interpretation of laboratory results in pregnant patients, necessitating trimester-specific reference intervals for haptoglobin. A multidisciplinary approach to patient care is crucial for accurate diagnosis and management.
NEW MATERIAL:Ephedrine derivatives expressed by formula I. EXAMPLE:p-Trifluoromethyl-ephedrine. USE:Pharmaceuticals. The compd. having CF2 group at the p-position shows strong adrenaline beta-blocking effect and is used for hypotensor, anti-stenocardiac agent and anti-arrhythmic agent. In case of the m-position, it shows motion stimulating effect, reserpine blepharoptosis inhibition and calcium antagonism and is useful as central nervous system stimulant anti-depressant and coronary vasodilator. In case of the o-position, it shows diuretic effect and is used for diuretic agent. PREPARATION:Trifluoromethyl propinic acid expressed by formula II and halogen such as bromine are reacted in a solvent such as actic acid to form a compd. expressed by formula III (x is Cl, Br or I), which is then reacted with benzylmethylamine in a solvent such as acetonitrile to form a compd. expressed by formula IV. The resultant product is catlitically reduced with a catalyst such as Pd/C to give the compd. expressed by formula I.
The present invention relates to the extraction process of flavone, particularly relate to the extracting method of a kind of total Flavonoids from Suaeda salsa, comprise the following steps: S1. plucks Herba suadeae glaucae stem and leaf, cleans, is dried, pulverizes, sieves, obtains Herba suadeae glaucae powder；S2. weigh Herba suadeae glaucae powder and add distilled water, adjusting pH value, adding enzymolysis under the conditions of compound enzyme vacuum tightness, extraction, be centrifuged, be filtrated to get supernatant a and filtering residue；S3. take supernatant a to concentrate, add ethanol, extraction, be centrifuged, filter to obtain supernatant b；S4. being concentrated by supernatant b, then add extract extraction, separate to obtain supernatant c, concentration, lyophilization obtain total flavones crude product；S5. by total flavones crude product, dissolving with distilled water, cross macroporous resin column, ethanol elution, collect eluent, concentration, lyophilization obtain refined total flavonoids.Extracting method technique in the present invention is simple, and easy to operate, the time is short, improves the extraction ratio of chromocor compound, and effectively removes chlorophyll, polysaccharide and other miscellaneous point, improves chromocor compound product purity.
Introduction: COVID-19 is an infectious disease caused by SARS-CoV2 (severe acute respiratory syndrome by the novo coronavirus). During the progression of COVID-19 infection, some patients may require noninvasive ventilation (NIV) or high-flow nasal catheter oxygen therapy (HFNC). However, its use has proved controversial in this population. Objective: To describe, retrospectively, possible predictor variables related to the use of NIV and HFNC, in order to associate them with their failure and consequent orotracheal intubation. Materials and Methods: observational, retrospective study, according to STROBE model, from the analysis of medical records, between March 2020 and July 2021. Study approved by a co-substantiated committee of D'or research and teaching institute (CAAE: 52534221.5.0000.5249). Inclusion criteria: over 18 years of age, diagnosis of positive COVID-19, hospitalized in the ICU of a tertiary Hospital located in Rio de Janeiro, admitted between March 2020 and July 2021. Exclusion criteria: hospital stay time of less than 3 days; patients who evolved to IOT in less than 48 hours; patients whose therapy (NIV, CNAF or NIV + CNAF) lasted less than 48 hours; patients whose medical records do not have the variables for the study. Primary outcome: incidence of orotracheal intubation. Secondary outcomes: time for orotracheal intubation, length of stay in the ICU and hospital and in-hospital mortality. Statistical analysis: There was no sample calculation due to the exploratory, descriptive and retrospective nature of this study. The Mann-Whitney U test will be applied to assess differences in icu length of stay. Survival time as well as hospital length of stay until the event will be analyzed with Kaplan-Meier estimates; the log-rank test will be used for group comparison. The p-\< 0.05 will be considered statistically significant. Preliminary results: 82.6% of the medical records completed phase 1 of data collection. Of these, 64.4% used CNAF, NIV or both. 20% of the medical records passed through phase 1 completed for phase 2 collection, with characterization of the population. The absence of heart disease and dementia, as well as the acute onset of symptoms (less than or equal to 10 days) and age (between 40 and 79 years) showed a statistically significant trend.
The present invention refers to aerosol formulations for administering drugs in an aqueous solution, more particularly, fluticasone propionate by inhalation. The invention provides novel aerosol formulations comprising (a) Fluticasone propionate, (b) a polar co-solvent, (c) a moisturizing agent, a lubricating agent or surfactant and (d) a hydrofluorocarbon (HFC) or hydrofluoroalkane (HFA) propellant. The formulation is characterized in that it is chlorofluorocarbon (CFC) propellant-free, containing non-solvated or modified fluticasone propionate in the surface thereof and the drug completely solubilized therein, which facilitates the absorption of the active principle by the airways. The invention ensures the uniformity of the doses administered in each shot and promotes the physical stability of the final formulation. The invention is further characterized in that the fluticasone propionate is drug-free and the formula is contained in a suitable aluminium container, which does not ha ve an inner coating. The present invention includes a non-conventional manufacturing method useful for dispensing the components of the formula without requiring freezing or especial environmental conditions, the same being practically, quickly and easily operated as especial cooling fittings are not required, the dispensing action can be adjusted during the process. Said method is more cost effective since an additional energy consumption is not required, and has the same advantages of the conventional filling method under cooling.
The study design is a single-dose, two-treatment, two-period, two-sequence cross over with a washout period of one to two weeks. Subject will be randomly assigned to two groups corresponding to two dosing sequences. Each subject will undergo two study (treatment) sessions, during which a single oral dose of 100mg metoprolol from either test or reference formulations will be administered. The estimated duration of subject's participation will be about 29-36 days (i.e. 3 weeks for screening and medication restraint, 1 day each for study (treatment) sessions I and II, 1 - 2 weeks as washout period. Venous blood samples will be collected at pre-dose (0h), and up to 24h post dose. The plasma concentrations of metoprolol will be determined by a validated assay. The non-compartmental method will be used to analyze the plasma concentration-time data and calculate the main pharmacokinetic parameters such as Cmax, Tmax, AUC0-last, AUC0-inf, and T1/2. ANOVA will be calculated on logarithmically transformed Cmax, AUC0-last and AUC0-inf. The two one sided tests will be used to calculate the 90% confidence intervals for the mean difference in AUC0-last, AUC0-inf and Cmax and to assess the bioequivalence of the two products
With the development of global social economy and the deepening of the aging population, diseases related to aging have received increasing attention. The pathogenesis of many respiratory diseases remains unclear, and lung aging is an independent risk factor for respiratory diseases. The aging mechanism of the lung may be involved in the occurrence and development of respiratory diseases. Aging-induced immune, oxidative stress, inflammation, and telomere changes can directly induce and promote the occurrence and development of lung aging. Meanwhile, the occurrence of lung aging also further aggravates the immune stress and inflammatory response of respiratory diseases; the two mutually affect each other and promote the development of respiratory diseases. Explaining the mechanism and treatment direction of these respiratory diseases from the perspective of lung aging will be a new idea and research field. This review summarizes the changes in pulmonary microenvironment, metabolic mechanisms, and the progression of respiratory diseases associated with aging.
PURPOSE:To provide a cosmetic stock having both excellent anti-inflammatory and skin roughness-curing effects, good in stability with time, high in safety, containing 6-hydroxyluteolin. CONSTITUTION:The objective compound containing a compound of the formula as active ingredient. This compound may be a synthetic or natural product, being not always required to be an isolated or synthesized pure product; mixtures, extracted products or partially purified products containing the same can also be used. The amount of said compound to be added is such as to be 0.001-20 (pref. 0.01-1) wt.% based on the whole cosmetic stock. The present cosmetic stock can be formulated with fatty oil, wax, hydrocarbon, fatty acid, alcohol, etc., unless the effect of said compound is impaired.
This "first-in-human" Phase I, single-center, dose escalation study (using 3 dose levels) is proposed to assess the safety of infusing reconstituted lyophilized human plasma (LyP). The study design incorporates plasmapheresis-derived autologous plasma (FFP) for infusion(s) to eliminate variables and events known to be related to allogenic transfusion. Subjects will be enrolled at a blood center and provide autologous FFP that will be shipped to the sponsor site and used as the starting material to manufacture LyP. Once manufacturing is complete, the LyP (autologous) will be returned to the blood center for reconstitution and infusion into subjects. Maximum dosage within this study will approach "massive transfusion" (1 liter in Cohort 3) to obtain a preliminary assessment of safety. One half of the FFP obtained from subjects in Cohort 3 (only) will be shipped to the sponsor and returned to the site (but not manufactured into LyP) to serve as the control (autologous FFP).
Hepatocellular carcinoma (HCC) is a common cancer, and it is the third commonest global cause of cancer-related death. With an increase in life-expectancy of the general population, the number of elderly with HCC is expected to increase. Current curative treatment options for HCC include: liver transplantation, liver resection (LR) and local ablation therapy. Liver transplantation is a good treatment for HCC within the Milan criteria (single HCC ≤ 5 cm or up to 3 nodules each \< 3 cm). As a consequence of the lack of liver donors, one relative contraindication for liver transplantation is age over 65 years, or the protocol requires elderly patients to have very good general health before they can be put on a transplant list. Transcatheter arterial chemoembolization (TACE) is used more commonly for the treatment of intermediate and advanced-staged HCC, while liver resection and local ablation therapy are used for early-staged HCC. Amongst the local ablative therapies, radiofrequency ablation (RFA) is most widely used. It has the advantage of minimally invasiveness, making it the first-line treatment for small HCC in patients with compromised liver function or associated severe medical conditions.

Elderly patients are more likely to have poor general conditions and associated medical diseases. RFA has the advantage of being less invasive and it causes less pain, less blood loss and earlier recovery than LR. On the other hand, incomplete ablation of HCC and tumor track seeding may happen. Several studies have demonstrated the safety of LR for elderly patients. There is no good evidence in the medical literature to support whether RFA or LR is a better treatment for elderly patients with HCC.
The efficacy of topotecan hydrochloride was evaluated in two clinical trials of 223 patients with metastatic ovarian cancer. All patients had disease that had recurred on, or was unresponsive to, a platinum-containing regimen. Patients in these trials received an initial dose of 1.5 mg/m2 as an intravenous infusion for 5 consecutive days, starting on Day 1 of a 21-day cycle. 

One trial (Study 039) was a randomized trial of 112 patients who received topotecan hydrochloride and of 114 patients who received paclitaxel (175 mg/m2 intravenously over 3 hours on Day 1 of a 21-day cycle). All patients had recurrent ovarian cancer after a platinum-containing regimen or had not responded to at least 1 prior platinum-containing regimen. Patients who did not respond to the trial therapy, or who progressed, could be given the alternative treatment. The efficacy outcome measures were overall response rate, response duration, time to progression, and overall survival (OS). 

The results of the trial did not show statistically significant improvements in response rates, response duration, time to progression, and OS as shown in Table 4. 

The median time to response was 7.6 weeks (3.1 weeks to 5 months) with topotecan hydrochloride compared with 6 weeks (2.4 weeks to 4.1 months) with paclitaxel. In the cross-over phase, 13% of 61 patients who received topotecan hydrochloride after paclitaxel had a partial response and 10% of 49 patients who received paclitaxel after topotecan hydrochloride had a response (2 complete responses). 

Topotecan hydrochloride was active in ovarian cancer patients who had developed resistance to platinum-containing therapy, defined as tumor progression while on, or tumor relapse within 6 months after completion of, a platinum-containing regimen. One complete and 6 partial responses were seen in 60 patients, for a response rate of 12%. In the same trial, there were no complete responders and 4 partial responders on the paclitaxel arm, for a response rate of 7%. 

Topotecan hydrochloride was also studied in an open-label, non-comparative trial in 111 patients with recurrent ovarian cancer after treatment with a platinum-containing regimen, or who had not responded to 1 prior platinum-containing regimen. The response rate was 14% (95% CI: 7%, 20%). The median duration of response was 5 months (4.6 weeks to 9.6 months). The time to progression was 2.6 months (5 days to 1.4 years). The median survival was 1.3 years (1.4 weeks, to 2.2 years).
BACKGROUND: Novel psychoactive substances (NPS) are a group of substances, mainly of synthetic origin, characterized by toxicological properties extremely dangerous. The main difficulty in recognizing NPS in seizures and biological samples lies in their dynamic nature, related to the continuous synthesis and introduction on the market of new drugs, often with very similar structures to existing ones. The aim of this study was the creation of a robust and versatile method for the analysis of traditional drugs and NPS in different matrices.
RESULTS: Both target analysis and suspect screening methodologies were developed. The strategy used for suspect screening allowed to collect data through a scheduled multi reaction monitoring (sMRM) survey which triggered the collection of enhanced product ion (EPI) spectra when a compound met information dependent acquisition (IDA) criteria. The retention time of the different drugs, which was crucial to define the sMRM survey scan parameters, was predicted with a Quantitative Structure Retention (Chromatographic) Relationship (QSRR) model by Multiple Linear Regression. The model was validated through the evaluation of training set predictions, an external validation set and a leave-one out strategy; the results showed that the method fit for its purpose. The target method was validated in oral fluid as a testing matrix, with excellent results in term of recovery, accuracy, precision and matrix effect. Finally, the performances of the suspect method were evaluated by analysing a mixture containing 8 reference standards not included in the initial dataset, as well as seizures and real oral fluid samples. Four NPS were putatively identified in the analysed samples.
SIGNIFICANCE: The advantage of the proposed approach is the possibility of quantifying 65 classical drugs of abuse and NPS and, at the same time, detect and putatively identify 146 additional drugs in one single LC-MS/MS run. This is an innovative strategy for multi analyte detection and enables detection of low concentrations of drugs in complex biological matrices such as oral fluid. Considering the highly dynamic drug market, a strength of this strategy is that the analytical method can be kept up to date through the addition of new compounds based on the last drug monitoring bodies alerts without the need of authentic standards.
FIELD: cosmetology. SUBSTANCE: method of oxidizing coloring of keratin fibers such as hair is in using of a coloring composition. The coloring composition contains at least one oxidizing color and oxidizing composition containing at least one oxidant. The coloring and/or oxidizing composition includes at least one combination of keramides type. EFFECT: hair coloring for prolonged time with shades of necessary intensity; stability of coloring to light, rain, hair waving and perspiration. 28 cl, 2 tbl
The present invention relates to a medicine for treating rheumatism and rheumatoid arthritis, which belongs to the field of traditional Chinese medicines. The medicine is prepared from thirteen natural Chinese herbal medicines of white peony root, eucommia bark, peucedanum root, lotus leaf, olibanum, ledebouriella root, safflower, costustoot, liquoric root, ladybell root, barbary wolfberry fruit, twotooth achyranthes root, indian bread with hostwood, etc. The prescription of the medicine of the present invention is unique, through the synergism and the supplementation of all medicinal components for body consolidation and strengthening, the functions of activating blood circulation to dissipate blood stasis, relaxing muscles and tendons and dredging channels are achieved. The sweat pores from head to foot of a patient can be opened quickly, and wind, coldness and noxious dampness are discharged from bones and joints, and wind, coldness and noxious dampness in the five viscera are discharged from bodies through excrement and urine; thus, the channels and collaterals from head to foot are opened, and rheumatism and rheumatoid arthritis are radically cured. At the same time, the medicine has good curative effect on raynauds disease, cervical spondylosis, periarthritis of shoulder, ankylosing spondylitis, etc. caused by cold and dampness. The present invention has the characteristics of simple preparation technology, low cost, significant and reliable curative effects, no relapse, no toxic and side effect, etc.; the total effective rate reaches 98.5%.
BACKGROUND: Longer-term symptoms (long COVID) may be present in seemingly recovered patients for several months and can be debilitating.
AIM: To investigate the prevalence and type of symptoms in those with a prior COVID-19 diagnosis.
METHODS: This prospective, longitudinal observational study commenced in July 2020 investigating the longer-term health impacts of COVID-19. Participants were recruited via public health units and media publicity. Surveys were completed upon enrolment, and at 1, 3, 6 and 12 months. Outcome measures included incidence of activity limitations and symptoms against health and vaccination status, age and gender.
RESULTS: Overall, 339 participants were recruited. At 3 months after COVID-19, 66.8% reported symptoms, and 44.8% were still experiencing symptoms at 12 months. Fatigue was most common at every point (between 53.1% and 33.1%). Pain symptoms increased in relative prevalence over time, whereas respiratory/pulmonary-type symptoms decreased substantially after 3 months. Females and younger people were more likely to experience symptoms in the early stages of long COVID (P < 0.01) and those with more comorbidities in the latter stages (P < 0.001). Vaccination showed a statistically significant protective effect against symptoms (P < 0.01-0.001).
CONCLUSION: Long-term COVID-19 symptoms exist among recovered patients up to 12 months after contracting the virus. Fatigue is a primary contributor, while chronic pain became more problematic after 6 months. Vaccination was a factor in preventing long-term symptoms and aiding faster recovery from symptoms. Further work exploring additional contributors to symptom prevalence would assist in developing appropriate follow-up care.
Lopinavir/ritonavir is an inhibitor of CYP3A and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co-administered with lopinavir and ritonavir. Thus, co-administration of lopinavir and ritonavir with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated. Co-administration with other CYP3A substrates may require a dose adjustment or additional monitoring as shown in Table 12. 

Additionally, lopinavir and ritonavir induces glucuronidation. 

Published data suggest that lopinavir is an inhibitor of OATP1B1.

These examples are a guide and not considered a comprehensive list of all possible drugs that may interact with lopinavir/ritonavir. The healthcare provider should consult appropriate references for comprehensive information.